224 related articles for article (PubMed ID: 32627609)
1. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production.
Dow JM; Mauri M; Scott TA; Wren BW
Expert Rev Vaccines; 2020 Jun; 19(6):507-527. PubMed ID: 32627609
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design.
Terra VS; Mills DC; Yates LE; Abouelhadid S; Cuccui J; Wren BW
J Med Microbiol; 2012 Jul; 61(Pt 7):919-926. PubMed ID: 22516134
[TBL] [Abstract][Full Text] [Related]
3. Glycoconjugate vaccines: current approaches towards faster vaccine design.
Micoli F; Del Bino L; Alfini R; Carboni F; Romano MR; Adamo R
Expert Rev Vaccines; 2019 Sep; 18(9):881-895. PubMed ID: 31475596
[No Abstract] [Full Text] [Related]
4. Direct Cloning of Bacterial Surface Polysaccharide Gene Cluster for One-Step Production of Glycoconjugate Vaccine.
Ma Z; Zhang H; Li L; Chen M; Wang PG
ACS Infect Dis; 2019 Jan; 5(1):74-78. PubMed ID: 30445812
[TBL] [Abstract][Full Text] [Related]
5. Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli.
Samaras JJ; Mauri M; Kay EJ; Wren BW; Micheletti M
Microb Cell Fact; 2021 May; 20(1):104. PubMed ID: 34030723
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the production of recombinant glycoconjugate vaccines.
Kay E; Cuccui J; Wren BW
NPJ Vaccines; 2019; 4():16. PubMed ID: 31069118
[TBL] [Abstract][Full Text] [Related]
7. Synthetic carbohydrate-based vaccines: challenges and opportunities.
Mettu R; Chen CY; Wu CY
J Biomed Sci; 2020 Jan; 27(1):9. PubMed ID: 31900143
[TBL] [Abstract][Full Text] [Related]
8. [Carbohydrates and vaccines: from purified polysaccharides to semi-synthetic glycoconjugate vaccines].
Mulard L
Ann Pharm Fr; 2007 Jan; 65(1):14-32. PubMed ID: 17299349
[TBL] [Abstract][Full Text] [Related]
9. Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins.
Cuccui J; Wren B
J Pharm Pharmacol; 2015 Mar; 67(3):338-50. PubMed ID: 25244672
[TBL] [Abstract][Full Text] [Related]
10. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs.
Berti F; Micoli F
Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in lipopolysaccharide-based glycoconjugate vaccines.
Zhu H; Rollier CS; Pollard AJ
Expert Rev Vaccines; 2021 Dec; 20(12):1515-1538. PubMed ID: 34550840
[TBL] [Abstract][Full Text] [Related]
12. Glycoconjugate vaccines: classic and novel approaches.
Adamo R
Glycoconj J; 2021 Aug; 38(4):397-398. PubMed ID: 34169357
[TBL] [Abstract][Full Text] [Related]
13. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
[TBL] [Abstract][Full Text] [Related]
14. Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines.
Adamo R
Acc Chem Res; 2017 May; 50(5):1270-1279. PubMed ID: 28463499
[TBL] [Abstract][Full Text] [Related]
15. Improving vaccines against
Kaplonek P; Khan N; Reppe K; Schumann B; Emmadi M; Lisboa MP; Xu FF; Calow ADJ; Parameswarappa SG; Witzenrath M; Pereira CL; Seeberger PH
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13353-13358. PubMed ID: 30530654
[No Abstract] [Full Text] [Related]
16. PglB function and glycosylation efficiency is temperature dependent when the pgl locus is integrated in the Escherichia coli chromosome.
Terra VS; Mauri M; Sannasiddappa TH; Smith AA; Stevens MP; Grant AJ; Wren BW; Cuccui J;
Microb Cell Fact; 2022 Jan; 21(1):6. PubMed ID: 34986868
[TBL] [Abstract][Full Text] [Related]
17. A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13.
Reglinski M; Ercoli G; Plumptre C; Kay E; Petersen FC; Paton JC; Wren BW; Brown JS
NPJ Vaccines; 2018; 3():53. PubMed ID: 30393571
[TBL] [Abstract][Full Text] [Related]
18. Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.
Micoli F; Adamo R; Costantino P
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914046
[TBL] [Abstract][Full Text] [Related]
19. Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.
Kay EJ; Mauri M; Willcocks SJ; Scott TA; Cuccui J; Wren BW
Microb Cell Fact; 2022 Apr; 21(1):66. PubMed ID: 35449016
[TBL] [Abstract][Full Text] [Related]
20. Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production.
Fiebig T; Litschko C; Freiberger F; Bethe A; Berger M; Gerardy-Schahn R
J Biol Chem; 2018 Jan; 293(3):953-962. PubMed ID: 29187601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
